Glabellar Frown Lines Clinical Trial
Official title:
A Single-arm Trial, Open-label, Repeated, Long-term, Multi-center, Phase IV Clinical Trial to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of Glabellar Lines With CORETOX®
Verified date | July 2020 |
Source | Medy-Tox |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | March 16, 2022 |
Est. primary completion date | June 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men and women aged between 20 and 65 - Patients attaining =grade 2 (moderate) in the investigator's rating of the severity of glabella lines at maximum frown - Patients who can comply with the study procedures and visit schedule - Patients who voluntarily sign the informed consent Exclusion Criteria: - Patients with medical conditions who may be at greater risk due to the administration of the investigational drugs (e.g.. diseases that may affect the neuromuscular action including Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis and motor neuropathy) - Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis - Patients who have received other procedures which may affect glabellar and forehead lines within 6 months - Patients who have received other procedures which may affect glabellar and forehead lines within 6 months - Patients who were injected with botulinum toxin within the past 3 months - Patients with allergy or hypersensitivity to the investigational drugs or their components - Patients who have bleeding tendency or taking anti-coagulant - Female subjects who are pregnant or lactating. Female subjects of childbearing age who have a plan to get pregnant during the study period, or do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.) - Patients with skin disorders or infection at the injection site - Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening - Patients who are unable to communicate or follow the instructions - Patients who are not eligible for this study based on the judgment of an investigator |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Medy-Tox |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Investigator-rated improvement rate of glabellar lines at maximum frown at Week 4 of each treatment cycle | Improvement rate: improvement of Facial Wrinkle Scale score from 3 (moderate) or 4 (severe) to 0 (none) or 1 (mild) | At Week 4 of each cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment). | |
Primary | Subject-rated improvement rate of glabellar lines at maximum frown | Every 4 weeks in each treatment cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment). | ||
Primary | Subject-rated satisfaction at each cycle after treatment | Every 4 weeks in each treatment cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment). | ||
Primary | Treatment on-set date | From baseline to Day 7 of each cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment). | ||
Primary | Treatment duration | From on-set date to next treatment (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment). | ||
Primary | Number of participants who experienced an adverse event | Baseline to Day 720 | ||
Primary | Number of participants with binding and neutralizing antibodies | Screening and Day 720 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02236312 -
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
|
Phase 2 | |
Active, not recruiting |
NCT05565950 -
AI-09 In Subjects With Glabellar Lines, GL-101
|
Phase 1/Phase 2 | |
Completed |
NCT00430963 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
Recruiting |
NCT05083286 -
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
|
Early Phase 1 | |
Completed |
NCT03687736 -
Subject Satisfaction With AbobutulinumtoxinA Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05623410 -
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 3 | |
Active, not recruiting |
NCT03440671 -
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT03736928 -
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
|
Phase 2 | |
Completed |
NCT01808742 -
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
|
N/A | |
Completed |
NCT00777803 -
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
Completed |
NCT00430586 -
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
|
Phase 2 | |
Completed |
NCT04281095 -
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 1/Phase 2 | |
Completed |
NCT05146999 -
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT02428608 -
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
|
Phase 2 | |
Completed |
NCT04143815 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
|
Phase 2 | |
Not yet recruiting |
NCT05305768 -
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
|
Early Phase 1 | |
Completed |
NCT05364580 -
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
Completed |
NCT05320393 -
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
|
Phase 2 | |
Completed |
NCT02677805 -
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
|
Phase 3 | |
Completed |
NCT01333397 -
Safety and Efficacy Study of Dysport RU and Glabellar Lines
|
Phase 2 |